trending Market Intelligence /marketintelligence/en/news-insights/trending/I8lzWe7vpvRDjkqQnIJj6w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AbbVie to carve out new Allergan Aesthetics unit following $84.2B deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AbbVie to carve out new Allergan Aesthetics unit following $84.2B deal

AbbVie Inc. will create a new business unit named Allergan Aesthetics following the company's $84.2 billion acquisition of Irish pharmaceutical giant Allergan PLC.

North Chicago, Ill.-based AbbVie said Allergan Aesthetics, to be based in Irvine, Calif., will include aesthetic products such as Botox Cosmetic, dermal fillers collection Juvederm and body-contouring treatment Coolsculpting.

Carrie Strom, senior vice president of U.S. medical aesthetics at Allergan, will be president of global Allergan Aesthetics and will report to AbbVie Chairman and CEO Richard Gonzalez.

AbbVie said Allergan's eye care and specialty businesses — including Botox Therapeutics, central nervous system, women's health and gastrointestinal diseases — will be integrated into AbbVie's existing business. Several Allergan employees have accepted leadership positions in the combined company across these particular franchises.

Gonzalez will head the future combined company as chairman and CEO. AbbVie Vice Chairman and Chief Commercial Officer Carlos Alban and Executive Vice President and CFO Robert Michael will continue in their roles at the combined company.

The future of Allergan CEO Brent Saunders was not detailed in AbbVie's Jan. 8 release. The executive is due to receive a $38.7 million compensation package if he is let go as part of the acquisition deal. Saunders previously agreed to join the AbbVie board after the transaction closes.

AbbVie expects to close the acquisition of Allergan in the first quarter.